Creating a treatment for neuromuscular diseases using anti-LTBP4.
Development of anti-LTBP4 as a biologic to treat Neuromuscular Diseases
This study is looking at a new treatment that targets a protein called LTBP4 to help improve muscle function and slow down Duchenne Muscular Dystrophy (DMD), so that patients can feel better and do more in their daily lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11064924 on NIH RePORTER |
What this research studies
This research focuses on developing a biologic treatment targeting Latent TGF-β Binding Protein 4 (LTBP4) to address neuromuscular disorders, particularly Duchenne Muscular Dystrophy (DMD). The approach involves understanding how LTBP4 influences muscle regeneration and fibrosis by regulating TGF-β activation, which is often excessive in these diseases. By targeting LTBP4, the research aims to improve muscle function and slow disease progression. Patients may benefit from a new therapeutic option that could enhance their quality of life and physical capabilities.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Duchenne Muscular Dystrophy or other related neuromuscular disorders.
Not a fit: Patients with neuromuscular disorders not related to LTBP4 or those who do not meet the specific inclusion criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that improves muscle function and slows the progression of neuromuscular diseases.
How similar studies have performed: While there have been advancements in treatments for neuromuscular diseases, targeting LTBP4 represents a novel approach that has not been extensively tested in clinical settings.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Demonbreun, Alexis R. — Northwestern University at Chicago
- Study coordinator: Demonbreun, Alexis R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.